Biomarkers and (pre-)diastolic dysfunction in the healthy elderly

Completed

• Conditions: Diastolic heart failure; Heart failure with preserved ejection fraction; 10019280

• Registration Number: NL-OMON45721
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1) Participant need to be 18 or above 18 years old
2) Participant need to be included in Lifelines Deep

Exclusion Criteria

1) Pregnancy

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To assess whether elevated galectin-3 and BNP could identify apparently healthy<br /><br>elderly subjects that are prone to develop diastolic dysfunction compared to<br /><br>those with low levels, in a case-control study design. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. To evaluate if a certain biomarker threshold can be determined to identify<br /><br>subjects at risk to develop diastolic dysfunction<br /><br>2. To evaluate differences whether or not galectin-3 or BNP are solely elevated<br /><br>to detect diastolic dysfunction<br /><br>3. To evaluate the influence of genetic variance on the development of<br /><br>diastolic dysfunction<br /><br>4. To evaluated if vascular stiffness (EndoPat) correlates with cardiac<br /><br>stiffness (diastolic dysfunction)</p><br>